Overview

Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

Assess the tolerability of quinagolide 200 μg/day in a dose-titration regimen in oocyte donors undergoing controlled ovarian hyperstimulation and at risk of developing OHSS Secondary Objectives Estimate the effects of a quinagolide dose-titration regimen compared to placebo in peritoneal fluid accumulation, incidence of ascites, OHSS symptoms and clinical laboratory parameters of haemoconcentration

Phase:

Phase 2

Details

Lead Sponsor:

Instituto Valenciano de Infertilidad, IVI VALENCIA

Treatments:

Quinagolide